Vaxcyte, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Grant E. Pickering
- Full Time Employees
- 507
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 825 Industrial Road San Carlos CA United States 94070
- IPO Date
- Jun 12, 2020
- CIK
- 0001649094
- Website
- vaxcyte.com
- Similar Companies
- Business
- Vaxcyte, Inc. is a clinical-stage vaccine innovation company specializing in engineering high-fidelity vaccines to protect against bacterial infectious diseases. Its core products include broad-spectrum pneumococcal conjugate vaccines (PCVs), notably VAX-24, a 24-valent vaccine aimed at preventing invasive pneumococcal disease, and VAX-31, a PCV with expanded coverage of over 30 strains designed for infants and adults. The company also develops other vaccine candidates such as VAX-A1, a prophylactic vaccine for Group A Streptococcus infections; VAX-PG, a therapeutic vaccine for periodontal disease; and VAX-GI, targeting dysentery and shigellosis. These products leverage site-specific, carrier-sparing conjugation technology to provide protection against both currently circulating and historically prevalent strains. Vaxcyte operates primarily in the United States and has pipeline products targeting public health segments involving bacterial infections, oral health, and infectious disease prevention. Founded in 2015 and headquartered in San Carlos, California, Vaxcyte has recently made significant strategic advances. In 2025, the company established a major fill-finish manufacturing partnership with Thermo Fisher Scientific valued at up to $1 billion to expand domestic commercial manufacturing capacity for its pneumococcal vaccines in Greenville, North Carolina, enhancing its U.S. supply chain and commercial readiness. This move supports U.S. biomanufacturing capabilities and anticipates upcoming product commercialization. Additionally, Vaxcyte is advancing clinical development milestones, including initiation of a pivotal Phase 3 adult study for VAX-31 in late 2025 and reporting of final Phase 2 positive dose-finding results for VAX-24 in infants. The FDA has granted Breakthrough Therapy designation to VAX-31 for pneumonia prevention, underscoring its clinical potential. The company maintains a strong cash position to fund operations through mid-2028 and recently appointed a Chief Commercial Officer to support commercialization efforts. Vaxcyte targets markets involving pneumococcal disease prevention, Group A strep infections, periodontal disease treatment, and gastrointestinal bacterial diseases across the United States and potentially global regions as its vaccines advance through regulatory approvals. Its product pipeline and manufacturing expansions position it competitively in the biotech vaccine sector, focused on broad-spectrum and high-fidelity vaccine innovation designed to address significant unmet medical needs in bacterial infectious diseases. This description synthesizes Vaxcyte’s business scope, product portfolio, recent strategic developments including manufacturing expansion, and clinical progress as of late 2025.
Company News
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale
Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027
Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
Vaxcyte shares surge on late-stage vaccine trial success
Vaxcyte (NASDAQ:PCVX) Stock Sees Heavy Call Option Buying
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High – Here’s Why
Vaxcyte Stock Hits New 52-Week High - Here's Why
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate